 |
| Global Gastric Motility Disorder Drug Market |
Market Overview
Gastric motility disorder drugs are indicated for the treatment of gastrointestinal motility disorders such as gastroparesis, a condition characterized by delayed gastric emptying. The key marketed drugs include metoclopramide, domperidone, erythromycin, and botulinum toxin. Orally administered drugs like metoclopramide and domperidone help improve gastric emptying and relieve nausea and vomiting. Botox injections aid in relieving gastric dysrhythmias by paralyzing part of the pylorus muscle. The rising prevalence of disorders like gastroparesis due to diabetes and other neurological conditions has fueled the demand for gastric motility disorder drugs.
The Global
Gastric Motility Disorder Drug Market is estimated to be valued at US$ 83.15 Bn in 2024 and is expected to
exhibit a CAGR of 5.4% over the
forecast period from 2024 to 2031.
Key Takeaways
Key players operating in the gastric motility disorder drug market are Pfizer
Inc., Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals, Sun
Pharmaceutical Industries Ltd., AbbVie Inc., Boehringer Ingelheim, Eli Lilly
and Company, Bristol Myers Squibb, Daiichi Sankyo Company, Limited, Bausch
Health Companies, Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals, Eisai
Co., Ltd., Ferring Pharmaceuticals, UCB, Evoke Pharma, and Cadila
Pharmaceuticals. These players are engaged in developing advanced drug
formulations and pipeline drugs to expand their product portfolios.
The growing prevalence of diabetes worldwide presents significant opportunities
for drug manufacturers in the gastric motility disorder market. Diabetic
gastroparesis accounts for over 80% of all gastroparesis cases. Rising
awareness about gastroparesis as a complication of diabetes is driving more
patients to seek medical treatment.
Key players are focusing on expanding their geographic presence and stepping up
initiatives in high growth emerging markets such as Asia Pacific, Middle East,
and Latin America. Strategic acquisitions and partnerships are enabling
companies to strengthen distribution networks and market position globally.
Market Drivers
Rising Geriatric Population: The risk of developing gastric motility disorders
increases with age. According to the United Nations, over 16% of the global
population will be aged 65 years and above by 2050. This vast geriatric
demographic presents a solid patient base for gastric motility drugs.
High Disease Burden of Diabetes: Diabetes is a leading cause of gastroparesis.
As per IDF estimates, over 537 million adults globally had diabetes in 2021.
Effective treatment of gastroparesis in diabetic patients helps control blood
sugar levels and prevent complications. This fuels demand for gastric motility
enhancing drugs.
Market Restraints
Stringent Regulatory Approvals: New drug formulations and pipeline drugs
require extensive clinical testing and regulatory clearances like FDA approval
before commercial launch. This significantly increases costs and delays market
entry.
Side Effects of Drugs: Drugs used to treat gastric disorders can cause adverse
effects like acute dystonic reactions, fatigue, headaches, and extrapyramidal
symptoms in some patients. This hampers medication adherence and overall
treatment effectiveness.
Segment Analysis
The gastric motility disorder drug market is dominated by the prokinetic agents
sub segment, which holds around 50% market share. Prokinetic agents directly
target the gastrointestinal tract and stimulates gastric emptying by increasing
gastrointestinal motility or the movement of digesting food through the GI
tract. They are preferred for the treatment of gastric motility disorders due
to their direct mechanism of action in enhancing gastric emptying and promoting
digestive motility.
The antiemetic sub segment is the second largest segment in the gastric
motility drug market. Antiemetics are used to prevent and treat nausea and
vomiting associated with gastric motility disorders. Drugs belonging to 5-HT3 receptor
antagonists and dopamine antagonists are majorly prescribed antiemetic drugs
for conditions like gastroparesis.
Global Analysis
Regionally, North America dominates the global gastric motility disorder drug
market and holds over 40% market share. Higher illness awareness,
well-established healthcare infrastructure and availability of advanced
treatment options drive the North American market. Asia Pacific is the fastest
growing region due to rising geriatric population, improving healthcare spending
and increasing investments by key players in developing countries. However,
limited diagnostic facilities and low treatment seeking rates in developing
Asia Pacific countries are major challenges. Europe is the second largest
market globally, with Germany, UK and France being the major country markets
due to supportive government initiatives and funding for gastrointestinal
disorder treatment.